首页> 外国专利> METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATION WITH BRAIN IRON ACCUMULATION

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATION WITH BRAIN IRON ACCUMULATION

机译:脑铁蓄积治疗神经变性的方法和药物成分

摘要

The present invention relates to methods and pharmaceutical compositions for the treatment of neurodegeneration in with brain iron accumulation (NBIA). Studying two novel genes, namely, CRAT encoding the carnitine acetyltransferase and REPS1 involved in endocytosis and vesicle transport, and a series of known NBIA genes, the inventors reported on iron overload related to increased levels and abnormal recycling of transferrin receptor as a common feature in NBIA. They ascribe this anomaly, at least in part, to impaired palmitoylation of the receptor as a common consequence of the various disease causing mutations. Finally, the inventors show that Artesunate improved TfR1 palmitoylation in NBIA fibroblasts. In particular, the present invention relates to a method of treating neurodegeneration with brain iron accumulation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a drug increasing TfR1 palmitoylation.
机译:本发明涉及用于治疗脑铁积聚(NBIA)中的神经变性的方法和药物组合物。研究两个新基因,即编码参与内吞作用和囊泡运输的肉毒碱乙酰基转移酶和REPS1的CRAT,以及一系列已知的NBIA基因,发明人报道了铁过量与转铁蛋白受体水平升高和异常回收有关,这是铁蛋白的共同特征。 NBIA。他们将此异常至少部分归因于受体的棕榈酰化受损,这是各种引起突变的疾病的普遍结果。最后,发明人表明青蒿琥酯改善了NBIA成纤维细胞中的TfR1棕榈酰化。特别地,本发明涉及在有需要的受试者中用脑铁蓄积治疗神经退行性疾病的方法,该方法包括给予该受试者治疗有效量的增加TfR1棕榈酰化的药物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号